Amicus Therapeutics (NASDAQ:FOLD) Announces Earnings Results, Misses Expectations By $0.07 EPS

Amicus Therapeutics (NASDAQ:FOLD) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.07), Zacks reports. Amicus Therapeutics had a negative net margin of 21.21% and a negative return on equity of 15.97%. Amicus Therapeutics updated its FY 2025 guidance to EPS.

Amicus Therapeutics Stock Performance

FOLD stock opened at $9.85 on Wednesday. The company’s 50-day moving average is $9.60 and its 200-day moving average is $10.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.02.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.88.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.